Merck Presents Interim Data From Phase 2a Trial Of Treatment For Pre-exposure Prophylaxis
KENILWORTH (NJ) (dpa-AFX) - Merck (MRK) Tuesday announced new interim data from the Phase 2a trial in adults evaluating the safety, tolerability and pharmacokinetics of islatravir, the company s investigational oral nucleoside reverse transcriptase translocation inhibitor, for pre-exposure prophylaxis.
Pre-exposure prophylaxis or PrEP is a way for people who do not have HIV but who are at very high risk of getting HIV to prevent HIV infection by taking a pill every day.
Interim findings demonstrate that once-monthly oral islatravir achieved the pre-specified efficacy PK threshold for PrEP at both of the two doses studied.
Merck Presents Interim Findings from Phase 2a Clinical Trial Evaluating Investigational Once-Monthly Oral Islatravir for the Prevention of HIV-1 Infection at HIVR4P 2021
Clinical Trial is Part of the Company’s HIV-1 Prevention Clinical Program Studying Islatravir as a Long-Acting PrEP Agent The company’s investigational oral nucleoside reverse transcriptase translocation inhibitor for pre-exposure prophylaxis . Interim findings demonstrate that once-monthly oral islatravir achieved the pre-specified efficacy PK threshold for PrEP at both of the two doses studied . In the interim … Clinical Trial is Part of the Company’s HIV-1 Prevention Clinical Program Studying Islatravir as a Long-Acting PrEP Agent
The company’s investigational oral nucleoside reverse transcriptase translocation inhibitor (NRTTI)for pre-exposure prophylaxis (PrEP). Interim findings demonstrate that once-monthly oral islatravir achieved the pre-specified efficacy PK threshold for PrEP at both of the t
Wednesday, 27 January 2021, 7:53 am
26 January 2021 – Important advances in HIV prevention
research were announced today at the 4th
HIV Research for Prevention Conference (HIVR4P //
Virtual), convened by IAS – the International AIDS
Society.
Highlights included findings from a pair of
trials evaluating whether infusions with a broadly
neutralizing antibody (bNAb) can prevent HIV acquisition and
positive interim results from a study of long-acting
injectable pre-exposure prophylaxis (PrEP) in women. Other
announcements included promising data from a study of
islatravir as a once-monthly PrEP pill, a study warning that
many African countries are not on track to meet key UNAIDS
prevention targets, new data on global uptake of PrEP, and a
Erie Times-News
Magee-Womens, UPMC Hamot marked its 10-year anniversary last week.
During its first decade, the hospital delivered more than 21,200 babies, a 66% increase from the previous 10 years at what was then Hamot Women s Hospital.
The hospital celebrated with special staff T-shirts and onesies for babies born during the week. Hamot Aid Society presented a gift basket to the first baby born on the anniversary.
Magee-Womens Research Institute and Foundation, which UPMC bills as the largest research institute in the U.S. dedicated to women’s health and reproductive biology, opened a new location at Magee-Womens in 2019.
•
Erie-based Logistics Plus has been re-certified by U.S. Customers and Border Protection as a Customs-Trade Partnership Against Terrorism participant.
Black women at higher risk of postpartum high BP compared to white women: JAMA medicaldialogues.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicaldialogues.in Daily Mail and Mail on Sunday newspapers.